Balaxi Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹81 crore and net profit of ₹1.15 crore for the September 2026 quarter.
Balaxi Pharmaceuticals (NSE: BALAXI) closed at ₹33.57 on 20 Nov 2026. Its market capitalisation is ₹185 crore and it trades at 55.0 times earnings.
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.